At a glance
- Originator Fidia Farmaceutici
- Class Anti-inflammatories; Glycolipids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Skin disorders
Most Recent Events
- 10 Oct 2003 Discontinued - Preclinical for Inflammation in Italy (unspecified route)
- 10 Oct 2003 Discontinued - Preclinical for Skin disorders in Italy (unspecified route)
- 02 Feb 2001 Profile reviewed but no significant changes made